Key result
Olezarsen reduced the incidence of acute pancreatitis by 85% compared to placebo (RR 0.15) in adults with severe hypertriglyceridemia.
Why the study?
Does olezarsen reduce triglyceride levels and the incidence of acute pancreatitis in adults with severe hypertriglyceridemia on stable lipid-lowering therapy?
RCT (n=1,061)
Double-blind
1:1:1
Does olezarsen reduce triglyceride levels and the incidence of acute pancreatitis in adults with severe hypertriglyceridemia on stable lipid-lowering therapy?
Relative Risk: 0.15 (95% CI 0.05–0.4)
Absolute Event Rate: 1.01% vs 6.23%
Number Needed to Treat: 20
p-value: p=<0.001
Pharmacologic silencing of APOC3 with olezarsen significantly reduces triglyceride levels and the incidence of acute pancreatitis in adults with severe hypertriglyceridemia, though it causes a dose-dependent increase in hepatic fat.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ando et al. (2026) conducted an RCT in Severe hypertriglyceridemia (n=1,061). Olezarsen vs. Placebo was evaluated on Adjudicated acute pancreatitis (RR 0.15, 95% CI 0.05-0.40, p=<0.001). Olezarsen reduced the incidence of acute pancreatitis by 85% compared to placebo (RR 0.15) in adults with severe hypertriglyceridemia.
Synapse has enriched 5 related papers. Consider them for comparative context: